Spero Therapeutics, Inc. filed a Form 8-K on October 27, 2026, disclosing that Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, following 11 years with the company, and that a post-retirement consulting arrangement is expected to be entered into around the same date.

Key Highlights

  • Retirement date: Timothy Keutzer, Chief Operating Officer of Spero Therapeutics, will retire effective December 31, 2026.
  • Consulting arrangement: The company expects to enter into a consulting agreement with Mr. Keutzer on or about December 31, 2026, for advisory and transition support services.
  • Consulting period: The arrangement is expected to run until approximately February 28, 2027, unless earlier terminated by either party on fifteen days' prior written notice.
  • Compensation: Mr. Keutzer will be paid an hourly rate for his services during the consulting period, according to the filing.
  • Tenure: The filing states Mr. Keutzer's retirement follows "11 years of dedicated service, leadership and significant contributions to the Company."

Spero Therapeutics Discloses COO Retirement and Post-Retirement Consulting Terms

According to the Form 8-K filed with the SEC on October 27, 2026, Spero Therapeutics, Inc. (NASDAQ:SPRO) announced on October 26, 2026, that Timothy Keutzer, the company's Chief Operating Officer, will retire from the company effective December 31, 2026. The filing was signed by Esther Rajavelu, identified as Chief Executive Officer and Chief Financial Officer of the company.

In connection with the retirement, the company disclosed it expects to enter into a consulting agreement with Mr. Keutzer on or about December 31, 2026. Under the terms described in the filing, Mr. Keutzer will provide advisory services to support the transition through approximately February 28, 2027. Either party may terminate the arrangement earlier by providing fifteen days' prior written notice. The filing states that Mr. Keutzer will be paid an hourly rate for services rendered during the consulting period, though no specific dollar amount was disclosed.

The filing was made under Item 5.02, which covers departure of directors or certain officers. The company characterized Mr. Keutzer's tenure as spanning 11 years, noting "dedicated service, leadership and significant contributions to the Company." No replacement or successor for the Chief Operating Officer role was named in the filing.

What Was Disclosed

Spero Therapeutics reported the planned retirement of COO Timothy Keutzer on December 31, 2026, and a post-retirement consulting arrangement expected to extend through approximately February 28, 2027, with hourly compensation and a fifteen-day termination notice provision.